Home | Welcome to Contract Pharma   
Last Updated Thursday, October 23 2014
Print RSS Feed

BMS, Samsung Bio Ink 10-Year Mfg. Pact



By Gil Roth



Published July 29, 2013
Bristol-Myers Squibb and Samsung BioLogics have entered into a 10-year agreement under which Samsung will manufacture a commercial antibody cancer drug for BMS at its recently completed plant in Songdo Incheon, South Korea.

Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.

"We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and chief executive officer of Samsung BioLogics. “The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.”

"Our agreement with Samsung is an important part of our company’s overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world,” said Louis Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb. “This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On